I hope so. The issue with all of this is time. I know we have 15 years exclusivity in Europe. But if takes another 5 years just to get all reimbursements in place, and then another several years to ramp up revenue, what is the real payback in terms of the stock price?
At least by 5-7 years, we might have some clarity on the Hikma lawsuit as well, even if it's not finalized.
I certainly hope they have something else in their back pocket, like the new formulation. It seems like that would be a game-changer.
Market Data 
Markets 
AI
